Open Access

Gefitinib-induced intestinal obstruction in advanced non-small cell lung carcinoma: A case report

  • Authors:
    • Yi‑Chen Liang
    • Gang Wu
    • Jing Cheng
    • Dan‑Dan Yu
    • Hong‑Ge Wu
  • View Affiliations

  • Published online on: July 8, 2015     https://doi.org/10.3892/ol.2015.3463
  • Pages: 1277-1280
  • Copyright: © Liang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gefitinib is an epidermal growth factor receptor (EGFR) inhibitor, which is used to treat patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. Dermatological reactions are the most common adverse events associated with gefitinib treatment; other adverse effects, including diarrhea, nausea, stomatitis and an asymptomatic elevation of liver enzymes have also been reported. The present study describes a patient with intestinal obstruction who was successfully undergoing treatment with gefitinib for primary and metastatic neoplasms. Gefitinib‑induced intestinal obstruction has not been previously reported; therefore, careful monitoring of gastrointestinal symptoms should be conducted throughout the course of gefitinib-treated malignancies.

References

1 

Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 18:2095–2103. 2000.PubMed/NCBI

2 

Ettinger DS: Clinical implications of EGFR expression in the development and progression of solid tumors: Focus on non-small cell lung cancer. Oncologist. 11:358–373. 2006. View Article : Google Scholar : PubMed/NCBI

3 

Haaland B, Tan PS, de Castro G Jr and Lopes G: Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations. J Thorac Oncol. 9:805–811. 2014. View Article : Google Scholar : PubMed/NCBI

4 

Faivre S, Delbaldo C, Vera K, et al: Safety, pharmacokinetic and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 24:25–35. 2006. View Article : Google Scholar : PubMed/NCBI

5 

Hartmann JT and Kanz L: Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition. Arch Dermatol. 144:1525–1526. 2008. View Article : Google Scholar : PubMed/NCBI

6 

Hotta K, Kiura K, Takigawa N, et al: Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer: The Okayama Lung Cancer Study Group experience. J Thorac Oncol. 5:179–184. 2010. View Article : Google Scholar : PubMed/NCBI

7 

Nakagawa M, Nishimura T, Teramukai S, et al: Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - a retrospective analysis: JMTO LC03-02. BMC Res Notes. 2:1572009. View Article : Google Scholar : PubMed/NCBI

8 

Passaro A, Di Maio M, Del Signore E, Gori B and de Marinis F: Management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: A comparison analysis. Clin Lung Cancer. 15:307–312. 2014. View Article : Google Scholar : PubMed/NCBI

9 

Madke B, Gole P, Kumar P and Khopkar U: Dermatological side effects of epidermal growth factor receptor inhibitors: ‘PRIDE’ complex. Indian J Dermatol. 59:271–274. 2014. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2015
Volume 10 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liang, Y., Wu, G., Cheng, J., Yu, D., & Wu, H. (2015). Gefitinib-induced intestinal obstruction in advanced non-small cell lung carcinoma: A case report. Oncology Letters, 10, 1277-1280. https://doi.org/10.3892/ol.2015.3463
MLA
Liang, Y., Wu, G., Cheng, J., Yu, D., Wu, H."Gefitinib-induced intestinal obstruction in advanced non-small cell lung carcinoma: A case report". Oncology Letters 10.3 (2015): 1277-1280.
Chicago
Liang, Y., Wu, G., Cheng, J., Yu, D., Wu, H."Gefitinib-induced intestinal obstruction in advanced non-small cell lung carcinoma: A case report". Oncology Letters 10, no. 3 (2015): 1277-1280. https://doi.org/10.3892/ol.2015.3463